Recent insider trends for Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) have caught the attention of investors. Patters in insider activity can help analysts formulate an outlook for a stock. In the case of CATB, the data has a lot to say about how the stock might perform going forward.
Institutions own 31.60% of Catabasis Pharmaceuticals, Inc. (CATB)’s shares. The total value of these holdings, in millions, is $9. Among active positions in the latest quarter, 16 holders increased their positions by a total of 442622 shares, 7 holders decreased the positions by a total of 463191 shares, and 6 holders held their positions. This works out to a net decrease in ownership of 20569 shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 7 holders initiated new positions by a total of 71780 shares and 5 holders exited their positions by a total of 393794 shares. This nets out to a decrease of 322014 shares and is another bearish sign for CATB.
Insider ownership increased by a total of 0 shares, which suggests that CATB’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: ownership increased by a net of 0 shares.
Analysts often look at short interest, or the number of shares currently being shorted by investors, to aid in their outlook for a particular stock. Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)’s short interest is 53400 shares, or 0.31% of the float. This represents an increase of 68% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
Supplementing insider data with technical indicators can help an investor form a more complete view on the outlook for a stock. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that CATB is a Weak buy, which implies that CATB is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) is undervalued.